Technical Analysis for NRIX - Nurix Therapeutics, Inc.

Grade Last Price % Change Price Change
F 26.225 -1.52% -0.41
NRIX closed down 8.55 percent on Monday, April 12, 2021, on 68 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down
Historical NRIX trend table...

Date Alert Name Type % Chg
MACD Bearish Signal Line Cross Bearish -1.52%
Wide Bands Range Expansion -1.52%
Down 3 Days in a Row Weakness -1.52%
Multiple of Ten Bearish Other -9.94%
Wide Bands Range Expansion -9.94%
20 DMA Resistance Bearish -17.51%
Wide Bands Range Expansion -17.51%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -22.00%
NR7 Range Contraction -22.00%
Inside Day Range Contraction -22.00%
Older End-of-Day Signals for NRIX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 2 hours ago
Fell Below Previous Day's Low about 2 hours ago
60 Minute Opening Range Breakdown about 2 hours ago
Down 1% about 2 hours ago
Up 5% about 4 hours ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Nurix Therapeutics, Inc. Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's lead product candidates in preclinical stage include NX-2127, an orally available Bruton's tyrosine kinase degrader for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B inhibitor for immuno-oncology indications. It also provides DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a class of enzymes that could modulate proteins within the cell. Nurix Therapeutics, Inc. has a strategic collaboration agreement with Gilead Sciences, Inc.; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was founded in 2009 and is headquartered in San Francisco, California.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Treatment Of Cancer Lymphoma Enzymes Immune Disorders Tyrosine Kinase Small Molecule Therapies Gilead Sciences Oncogene Bruton Bruton's Tyrosine Kinase

Is NRIX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 52.38
52 Week Low 15.21
Average Volume 530,769
200-Day Moving Average 0.00
50-Day Moving Average 35.91
20-Day Moving Average 33.20
10-Day Moving Average 30.75
Average True Range 3.99
ADX 18.24
+DI 16.14
-DI 26.81
Chandelier Exit (Long, 3 ATRs ) 35.77
Chandelier Exit (Short, 3 ATRs ) 38.01
Upper Bollinger Band 44.64
Lower Bollinger Band 21.77
Percent B (%b) 0.21
BandWidth 68.89
MACD Line -2.02
MACD Signal Line -1.80
MACD Histogram -0.227
Fundamentals Value
Market Cap 1.03 Billion
Num Shares 38.9 Million
EPS -1.82
Price-to-Earnings (P/E) Ratio -14.60
Price-to-Sales 113.01
Price-to-Book 4.77
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.18
Resistance 3 (R3) 31.53 30.37 30.42
Resistance 2 (R2) 30.37 29.21 30.19 30.16
Resistance 1 (R1) 28.50 28.50 27.92 28.15 29.91
Pivot Point 27.34 27.34 27.05 27.16 27.34
Support 1 (S1) 25.47 26.18 24.89 25.12 23.35
Support 2 (S2) 24.31 25.47 24.13 23.10
Support 3 (S3) 22.44 24.31 22.84
Support 4 (S4) 22.09